Concepts (204)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bipolar Disorder | 33 | 2024 | 347 | 7.960 |
Why?
|
| Depressive Disorder, Major | 8 | 2024 | 401 | 1.440 |
Why?
|
| Antipsychotic Agents | 7 | 2024 | 375 | 1.350 |
Why?
|
| Suicide | 5 | 2024 | 176 | 1.230 |
Why?
|
| Depressive Disorder | 4 | 2019 | 451 | 1.170 |
Why?
|
| Lithium Compounds | 3 | 2020 | 14 | 1.010 |
Why?
|
| Antimanic Agents | 5 | 2023 | 37 | 0.940 |
Why?
|
| Genital Neoplasms, Female | 1 | 2024 | 46 | 0.910 |
Why?
|
| Emotions | 4 | 2023 | 363 | 0.900 |
Why?
|
| Suicidal Ideation | 3 | 2024 | 215 | 0.860 |
Why?
|
| Hippocampus | 6 | 2019 | 812 | 0.800 |
Why?
|
| Facial Expression | 1 | 2019 | 28 | 0.640 |
Why?
|
| Attention | 2 | 2020 | 194 | 0.620 |
Why?
|
| Anxiety | 3 | 2024 | 956 | 0.600 |
Why?
|
| Lithium | 2 | 2023 | 66 | 0.580 |
Why?
|
| Magnetic Resonance Imaging | 15 | 2023 | 3526 | 0.550 |
Why?
|
| Substance-Related Disorders | 3 | 2022 | 458 | 0.530 |
Why?
|
| Cerebral Cortex | 1 | 2019 | 434 | 0.520 |
Why?
|
| Benzodiazepines | 2 | 2013 | 101 | 0.510 |
Why?
|
| Depression | 6 | 2024 | 1225 | 0.470 |
Why?
|
| Amygdala | 3 | 2021 | 81 | 0.460 |
Why?
|
| Breast Neoplasms | 1 | 2024 | 2486 | 0.400 |
Why?
|
| Adolescent | 13 | 2024 | 19093 | 0.380 |
Why?
|
| Humans | 48 | 2024 | 123146 | 0.380 |
Why?
|
| Neuroimaging | 5 | 2021 | 332 | 0.350 |
Why?
|
| Gray Matter | 3 | 2020 | 30 | 0.330 |
Why?
|
| Impulsive Behavior | 2 | 2021 | 144 | 0.330 |
Why?
|
| Child | 14 | 2023 | 24221 | 0.320 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 6 | 2024 | 202 | 0.300 |
Why?
|
| Marijuana Abuse | 2 | 2022 | 48 | 0.290 |
Why?
|
| White Matter | 2 | 2022 | 181 | 0.290 |
Why?
|
| Child Abuse | 2 | 2023 | 195 | 0.280 |
Why?
|
| Organ Size | 5 | 2019 | 412 | 0.260 |
Why?
|
| Female | 27 | 2024 | 65443 | 0.260 |
Why?
|
| Putamen | 1 | 2024 | 19 | 0.230 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2024 | 34 | 0.230 |
Why?
|
| Milk Banks | 1 | 2023 | 4 | 0.230 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2024 | 104 | 0.220 |
Why?
|
| Cyclothymic Disorder | 1 | 2023 | 3 | 0.220 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2024 | 90 | 0.220 |
Why?
|
| Temperament | 1 | 2023 | 25 | 0.210 |
Why?
|
| Self-Injurious Behavior | 1 | 2024 | 64 | 0.210 |
Why?
|
| Brain | 4 | 2021 | 2946 | 0.210 |
Why?
|
| Stress, Psychological | 2 | 2020 | 557 | 0.210 |
Why?
|
| Cognition | 3 | 2023 | 735 | 0.200 |
Why?
|
| Trazodone | 1 | 2022 | 7 | 0.200 |
Why?
|
| Male | 22 | 2024 | 60034 | 0.200 |
Why?
|
| Cross-Sectional Studies | 5 | 2023 | 3380 | 0.200 |
Why?
|
| Adult | 18 | 2024 | 29029 | 0.200 |
Why?
|
| Cannabis | 1 | 2022 | 41 | 0.200 |
Why?
|
| Hallucinogens | 1 | 2022 | 41 | 0.190 |
Why?
|
| Endophenotypes | 1 | 2021 | 13 | 0.190 |
Why?
|
| Depressive Disorder, Treatment-Resistant | 1 | 2023 | 115 | 0.190 |
Why?
|
| Milk, Human | 1 | 2023 | 300 | 0.180 |
Why?
|
| Aggression | 2 | 2021 | 226 | 0.180 |
Why?
|
| Suicide, Attempted | 2 | 2019 | 132 | 0.180 |
Why?
|
| Psychiatric Status Rating Scales | 6 | 2024 | 804 | 0.180 |
Why?
|
| Yoga | 1 | 2020 | 12 | 0.180 |
Why?
|
| Meditation | 1 | 2020 | 16 | 0.170 |
Why?
|
| Pituitary-Adrenal System | 1 | 2019 | 36 | 0.170 |
Why?
|
| Nucleus Accumbens | 1 | 2020 | 54 | 0.170 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2019 | 65 | 0.170 |
Why?
|
| Happiness | 1 | 2019 | 10 | 0.160 |
Why?
|
| Adult Survivors of Child Adverse Events | 1 | 2019 | 15 | 0.160 |
Why?
|
| Atrophy | 2 | 2016 | 225 | 0.160 |
Why?
|
| Evoked Potentials | 1 | 2019 | 133 | 0.160 |
Why?
|
| Young Adult | 7 | 2019 | 8864 | 0.150 |
Why?
|
| Electroencephalography | 1 | 2023 | 862 | 0.150 |
Why?
|
| Bayes Theorem | 1 | 2019 | 278 | 0.150 |
Why?
|
| Fear | 1 | 2019 | 202 | 0.150 |
Why?
|
| Circadian Rhythm | 1 | 2019 | 269 | 0.150 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2020 | 215 | 0.140 |
Why?
|
| Antidepressive Agents | 4 | 2023 | 287 | 0.140 |
Why?
|
| Adult Survivors of Child Abuse | 1 | 2017 | 13 | 0.140 |
Why?
|
| Neuropsychological Tests | 1 | 2021 | 921 | 0.140 |
Why?
|
| Mood Disorders | 3 | 2023 | 123 | 0.140 |
Why?
|
| Life Change Events | 1 | 2017 | 59 | 0.140 |
Why?
|
| Middle Aged | 11 | 2024 | 25964 | 0.140 |
Why?
|
| Psychomotor Agitation | 2 | 2014 | 56 | 0.130 |
Why?
|
| Time | 1 | 2016 | 94 | 0.130 |
Why?
|
| Psychological Tests | 1 | 2016 | 92 | 0.130 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2024 | 226 | 0.130 |
Why?
|
| Models, Neurological | 1 | 2017 | 204 | 0.130 |
Why?
|
| Neuroprotective Agents | 1 | 2016 | 146 | 0.120 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2014 | 26 | 0.120 |
Why?
|
| Mental Disorders | 2 | 2012 | 828 | 0.120 |
Why?
|
| Anxiety Disorders | 1 | 2019 | 677 | 0.110 |
Why?
|
| Case-Control Studies | 5 | 2020 | 3251 | 0.110 |
Why?
|
| Quinolones | 1 | 2013 | 54 | 0.100 |
Why?
|
| Memantine | 1 | 2012 | 17 | 0.100 |
Why?
|
| Factitious Disorders | 1 | 2012 | 2 | 0.100 |
Why?
|
| Chernobyl Nuclear Accident | 1 | 2012 | 6 | 0.100 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2012 | 94 | 0.100 |
Why?
|
| Risk Factors | 2 | 2024 | 10011 | 0.100 |
Why?
|
| Malformations of Cortical Development | 1 | 2012 | 53 | 0.100 |
Why?
|
| Panic Disorder | 1 | 2012 | 45 | 0.100 |
Why?
|
| Stalking | 1 | 2011 | 5 | 0.090 |
Why?
|
| Piperazines | 1 | 2013 | 231 | 0.090 |
Why?
|
| Arnold-Chiari Malformation | 1 | 2012 | 51 | 0.090 |
Why?
|
| Sandfly fever Naples virus | 1 | 2010 | 2 | 0.090 |
Why?
|
| Bunyaviridae Infections | 1 | 2010 | 7 | 0.090 |
Why?
|
| Meningitis, Aseptic | 1 | 2010 | 14 | 0.090 |
Why?
|
| Encephalitis, Viral | 1 | 2010 | 22 | 0.090 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 1 | 2010 | 32 | 0.090 |
Why?
|
| Clozapine | 1 | 2010 | 24 | 0.090 |
Why?
|
| Biomarkers | 1 | 2019 | 2943 | 0.090 |
Why?
|
| Cytochrome P-450 CYP1A2 | 1 | 2010 | 48 | 0.090 |
Why?
|
| Psychotic Disorders | 1 | 2012 | 140 | 0.090 |
Why?
|
| Disease Progression | 1 | 2016 | 2023 | 0.090 |
Why?
|
| Personality | 1 | 2010 | 103 | 0.080 |
Why?
|
| Pancreatitis | 1 | 2010 | 130 | 0.080 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 2848 | 0.080 |
Why?
|
| Double-Blind Method | 2 | 2023 | 1588 | 0.080 |
Why?
|
| Gyrus Cinguli | 2 | 2023 | 114 | 0.080 |
Why?
|
| Aged | 5 | 2024 | 19068 | 0.080 |
Why?
|
| Inpatients | 1 | 2011 | 492 | 0.070 |
Why?
|
| Italy | 2 | 2020 | 112 | 0.070 |
Why?
|
| Cerebellum | 2 | 2023 | 415 | 0.070 |
Why?
|
| Surveys and Questionnaires | 3 | 2024 | 3659 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2013 | 6027 | 0.060 |
Why?
|
| Temporal Lobe | 2 | 2019 | 116 | 0.060 |
Why?
|
| Tropanes | 1 | 2024 | 2 | 0.060 |
Why?
|
| Retrospective Studies | 5 | 2024 | 16000 | 0.060 |
Why?
|
| Anhedonia | 1 | 2024 | 30 | 0.060 |
Why?
|
| Child, Preschool | 1 | 2019 | 13878 | 0.060 |
Why?
|
| Mice | 1 | 2019 | 17486 | 0.050 |
Why?
|
| Anisotropy | 1 | 2022 | 122 | 0.050 |
Why?
|
| Dopamine | 1 | 2024 | 275 | 0.050 |
Why?
|
| Corpus Callosum | 1 | 2022 | 98 | 0.050 |
Why?
|
| Breast Feeding | 1 | 2023 | 220 | 0.050 |
Why?
|
| Calcium Channels, L-Type | 1 | 2021 | 53 | 0.050 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2022 | 239 | 0.050 |
Why?
|
| Communicable Disease Control | 1 | 2022 | 141 | 0.040 |
Why?
|
| Animals | 2 | 2019 | 33718 | 0.040 |
Why?
|
| Mothers | 1 | 2023 | 350 | 0.040 |
Why?
|
| Pregnancy Outcome | 1 | 2024 | 597 | 0.040 |
Why?
|
| Psychotropic Drugs | 2 | 2012 | 125 | 0.040 |
Why?
|
| Treatment Outcome | 4 | 2023 | 12116 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2020 | 229 | 0.040 |
Why?
|
| Health | 1 | 2019 | 38 | 0.040 |
Why?
|
| Reward | 1 | 2020 | 106 | 0.040 |
Why?
|
| Pregnancy Complications | 1 | 2024 | 507 | 0.040 |
Why?
|
| Age Factors | 2 | 2016 | 2799 | 0.040 |
Why?
|
| Students | 1 | 2020 | 253 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 1069 | 0.040 |
Why?
|
| Anticonvulsants | 2 | 2011 | 370 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2023 | 826 | 0.040 |
Why?
|
| Self Report | 1 | 2020 | 514 | 0.040 |
Why?
|
| Interview, Psychological | 1 | 2017 | 99 | 0.030 |
Why?
|
| Rest | 1 | 2017 | 60 | 0.030 |
Why?
|
| Psychometrics | 1 | 2020 | 667 | 0.030 |
Why?
|
| Pregnancy | 2 | 2024 | 7142 | 0.030 |
Why?
|
| Internal Capsule | 1 | 2016 | 51 | 0.030 |
Why?
|
| Thalamus | 1 | 2016 | 85 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2017 | 1011 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 1105 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2021 | 1641 | 0.030 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2013 | 25 | 0.030 |
Why?
|
| Aripiprazole | 1 | 2013 | 21 | 0.030 |
Why?
|
| Quality of Life | 1 | 2023 | 1932 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1312 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2013 | 96 | 0.030 |
Why?
|
| Time Factors | 2 | 2013 | 6205 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2013 | 5046 | 0.030 |
Why?
|
| Injections, Intramuscular | 1 | 2013 | 192 | 0.030 |
Why?
|
| Machiavellianism | 1 | 2012 | 2 | 0.030 |
Why?
|
| Munchausen Syndrome by Proxy | 1 | 2012 | 5 | 0.020 |
Why?
|
| Septum of Brain | 1 | 2012 | 5 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2012 | 150 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2021 | 2585 | 0.020 |
Why?
|
| Forensic Psychiatry | 1 | 2012 | 13 | 0.020 |
Why?
|
| Locus Coeruleus | 1 | 2012 | 22 | 0.020 |
Why?
|
| Prodromal Symptoms | 1 | 2012 | 9 | 0.020 |
Why?
|
| Romania | 1 | 2011 | 6 | 0.020 |
Why?
|
| Reactive Attachment Disorder | 1 | 2011 | 5 | 0.020 |
Why?
|
| Lithium Carbonate | 1 | 2011 | 21 | 0.020 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2012 | 69 | 0.020 |
Why?
|
| Schizophrenia, Paranoid | 1 | 2010 | 11 | 0.020 |
Why?
|
| Gliosis | 1 | 2010 | 32 | 0.020 |
Why?
|
| Endemic Diseases | 1 | 2010 | 58 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2024 | 8104 | 0.020 |
Why?
|
| Epilepsies, Partial | 1 | 2010 | 91 | 0.020 |
Why?
|
| Valproic Acid | 1 | 2011 | 165 | 0.020 |
Why?
|
| Schizophrenia | 1 | 2013 | 300 | 0.020 |
Why?
|
| Patient Admission | 1 | 2011 | 184 | 0.020 |
Why?
|
| Occupational Exposure | 1 | 2010 | 129 | 0.020 |
Why?
|
| Behavior Therapy | 1 | 2012 | 256 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2011 | 311 | 0.020 |
Why?
|
| Comorbidity | 1 | 2014 | 1497 | 0.020 |
Why?
|
| Syndrome | 1 | 2012 | 1115 | 0.020 |
Why?
|
| Sexual Behavior | 1 | 2010 | 235 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2010 | 218 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 2837 | 0.020 |
Why?
|
| Personality Disorders | 1 | 2011 | 158 | 0.020 |
Why?
|
| Infant | 1 | 2023 | 12339 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 1796 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 1088 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2012 | 388 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 1240 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 6372 | 0.020 |
Why?
|
| Hospitalization | 1 | 2013 | 1733 | 0.010 |
Why?
|
| Genotype | 1 | 2010 | 2540 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2010 | 1134 | 0.010 |
Why?
|
| Prevalence | 1 | 2010 | 2405 | 0.010 |
Why?
|